Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1072-1077

  Sher, D J ^a,b   Tishler, R B ^a   Annino, D ^a   Punglia, R S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cost effectiveness analysis; Neck dissection; PET CT; Radiotheraphy

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; MATHEMATICAL MODEL; MINIMAL RESIDUAL DISEASE; NECK DISSECTION; OROPHARYNX CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY DOSAGE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77949275903     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp405     Document Type: Article

References (29)

1. Harpole DH Jr, Herndon JE II, Young WG Jr et al. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76: 787-796.
2. Donatelli-Lassig AA, Duffy SA, Fowler KE et al. The effect of neck dissection on quality of life after chemoradiation. Otolaryngol Head Neck Surg 2008; 139: 511-518.
3. Stuiver MM, van Wilgen CP, de Boer EM et al. Impact of shoulder complaints after neck dissection on shoulder disability and quality of life. Otolaryngol Head Neck Surg 2008; 139: 32-39.
4. Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
5. Lango MN, Myers JN, Garden AS. Controversies in surgical management of the node-positive neck after chemoradiation. Semin Radiat Oncol 2009; 19: 24-28.
6. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-338.
7. Garden AS, Harris J, Trotti A et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008; 71: 1351-1355.
8. Ang KK, Harris J, Garden AS et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005; 23: 3008-3015.
9. Lang K, Marciniak MD, Faries D et al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health 2008; 12(4): 481-488.
10. Hollenbeak CS, Lowe VJ, Stack BC Jr. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer 2001; 92: 2341-2348.
11. Janot F, de Raucourt D, Benhamou E et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26: 5518-5523.
12. IRP Web Medicare DRG/Calculator. http://www.drg.irp.com/cgi-bin/webplus.exe?Script=/irpsys/drgcalc.wml; (March 2009, date last accessed).
13. Emanuel EJ, Ash A, Yu W et al. Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med 2002; 162: 1722-1728.
14. McHam SA, Adelstein DJ, Rybicki LA, Lavertu P, Esclamado RM, Wood BG et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? Head Neck 2003; 25(10): 791-798.
15. Frank DK, Hu KS, Culliney BE, Persky MS, Nussbaum M, Schantz SP et al. Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer. Laryngoscope 2005; 115(6): 1015-1020.
16. Lango MN, Andrews GA, Ahmad S, Feigenberg S, Tuluc M, Gaughan J et al. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis. Head Neck 2009; 31: 328-337.
17. Liauw SL, Amdur RJ, Morris CG, Werning JW, Villaret DB, Mendenhall WM. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. Head Neck 2007; 29(8): 715-719.
18. Lavertu P, Adelstein DJ, Saxton JP, Secic M, Wanamaker JR, Eliachar I et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 1997; 19(7): 559-566.
19. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23(15): 3562-3567.
20. Inohara H, Enomoto K, Tomiyama Y, Yoshii T, Osaki Y, Higuchi I et al. The role of CT and (18)F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol 2008 October 7 [Epub ahead of print].
21. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33: 210-222.
22. Shenfine J, McNamee P, Steen N et al. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess 2005; 9: iii, 1-121.
23. Wildi SM, Cox MH, Clark LL et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004; 99: 1044-1049.
24. 2008 Medicare Part B Fee Schedule Calculator 2008; http://www.highmarkmedicareservices.com/partb/reimbursement/calc-2008.ht ml (March 2009, date last accessed).
25. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507.
26. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-511(discussion 511-513).
27. Lejeune C, Bismuth MJ, Conroy T et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005; 46: 2020-2028.
28. Verboom P, van Tinteren H, Hoekstra OS et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003; 30: 1444-1449.
29. Nouraei SA, Upile T, Al-Yaghchi C et al. Role of planned postchemoradiotherapy selective neck dissection in the multimodality management of head and neck cancer. Laryngoscope 2008; 118: 797-803.